Skip to main content
Top
Published in:

Open Access 27-04-2024 | Anaplastic Large Cell Lymphoma | Commentary

Podcast on Emerging Treatment Options for Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumors

Authors: Eric Lowe, Yael P. Mossé

Published in: Oncology and Therapy | Issue 2/2024

Login to get access

Abstract

Anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT) are rare cancers observed predominantly in children and young adults. ALCL accounts for 10–15% of all pediatric non-Hodgkin lymphomas and is commonly diagnosed at an advanced stage of disease. In children, 84–91% of cases of ALCL harbor an anaplastic lymphoma kinase (ALK) gene translocation. IMT is a rare mesenchymal neoplasm that also tends to occur in children and adolescents. Approximately 50–70% of IMT cases involve rearrangements in the ALK gene. A combination of chemotherapeutic drugs is typically used for children with ALK-positive ALCL, and the only known curative therapy for ALK-positive IMT is complete surgical resection. Crizotinib, a first-generation ALK inhibitor, was approved in the USA in 2021 for pediatric patients and young adults with relapsed or refractory ALK-positive ALCL; however, its safety and efficacy have not been established in older adults. In 2022, crizotinib was approved for adult and pediatric patients with unresectable, recurrent, or refractory ALK-positive IMT. This podcast provides an overview of ALK-positive ALCL and IMT. We discuss the current treatment landscape, the role of ALK tyrosine kinase inhibitors, and areas of future research.
Literature
1.
go back to reference Kinney MC, Higgins RA, Medina EA. Anaplastic large cell lymphoma: twenty-five years of discovery. Arch Pathol Lab Med. 2011;135:19–43.CrossRefPubMed Kinney MC, Higgins RA, Medina EA. Anaplastic large cell lymphoma: twenty-five years of discovery. Arch Pathol Lab Med. 2011;135:19–43.CrossRefPubMed
2.
go back to reference Lowe EJ, Gross TG. Anaplastic large cell lymphoma in children and adolescents. Pediatr Hematol Oncol. 2013;30:509–19.CrossRefPubMed Lowe EJ, Gross TG. Anaplastic large cell lymphoma in children and adolescents. Pediatr Hematol Oncol. 2013;30:509–19.CrossRefPubMed
4.
go back to reference Irshaid L, Xu ML. ALCL by any other name: the many facets of anaplastic large cell lymphoma. Pathology. 2020;52:100–10.CrossRefPubMed Irshaid L, Xu ML. ALCL by any other name: the many facets of anaplastic large cell lymphoma. Pathology. 2020;52:100–10.CrossRefPubMed
6.
go back to reference Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.CrossRefPubMedPubMedCentral Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.CrossRefPubMedPubMedCentral
7.
go back to reference Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131:39–49.CrossRefPubMed Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131:39–49.CrossRefPubMed
8.
go back to reference Falini B, Martelli MP. Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy. Haematologica. 2009;94:897–900.CrossRefPubMedPubMedCentral Falini B, Martelli MP. Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy. Haematologica. 2009;94:897–900.CrossRefPubMedPubMedCentral
9.
go back to reference Prokoph N, Larose H, Lim MS, Amos Burke GA, Turner SD. Treatment options for paediatric anaplastic large cell lymphoma (ALCL): current standard and beyond. Cancers (Basel). 2018;10:99.CrossRefPubMedPubMedCentral Prokoph N, Larose H, Lim MS, Amos Burke GA, Turner SD. Treatment options for paediatric anaplastic large cell lymphoma (ALCL): current standard and beyond. Cancers (Basel). 2018;10:99.CrossRefPubMedPubMedCentral
11.
go back to reference Le Deley MC, Rosolen A, Williams DM, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol. 2010;28:3987–93.CrossRefPubMed Le Deley MC, Rosolen A, Williams DM, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol. 2010;28:3987–93.CrossRefPubMed
12.
go back to reference Lowe EJ, Reilly AF, Lim MS, et al. Crizotinib in combination with chemotherapy for pediatric patients with ALK+ anaplastic large-cell lymphoma: the results of Children’s Oncology Group trial ANHL12P1. J Clin Oncol. 2022;41:2043–53.CrossRefPubMedPubMedCentral Lowe EJ, Reilly AF, Lim MS, et al. Crizotinib in combination with chemotherapy for pediatric patients with ALK+ anaplastic large-cell lymphoma: the results of Children’s Oncology Group trial ANHL12P1. J Clin Oncol. 2022;41:2043–53.CrossRefPubMedPubMedCentral
13.
go back to reference Brugières L, Pacquement H, Le Deley MC, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol. 2009;27:5056–61.CrossRefPubMed Brugières L, Pacquement H, Le Deley MC, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol. 2009;27:5056–61.CrossRefPubMed
14.
go back to reference Brugières L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27:897–903.CrossRefPubMed Brugières L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27:897–903.CrossRefPubMed
15.
go back to reference Beishuizen A, Mellgren K, Andrés M, et al. Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma. Lancet Haematol. 2023;10:e213–24.CrossRefPubMed Beishuizen A, Mellgren K, Andrés M, et al. Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma. Lancet Haematol. 2023;10:e213–24.CrossRefPubMed
18.
go back to reference Panagiotopoulos N, Patrini D, Gvinianidze L, Woo WL, Borg E, Lawrence D. Inflammatory myofibroblastic tumour of the lung: a reactive lesion or a true neoplasm? J Thorac Dis. 2015;7:908–11.PubMedPubMedCentral Panagiotopoulos N, Patrini D, Gvinianidze L, Woo WL, Borg E, Lawrence D. Inflammatory myofibroblastic tumour of the lung: a reactive lesion or a true neoplasm? J Thorac Dis. 2015;7:908–11.PubMedPubMedCentral
19.
go back to reference Sachdev R, Mohapatra I, Goel S, Ahlawat K, Sharma N. Core biopsy diagnosis of ALK positive inflammatory myofibroblastic tumor of lung: an interesting case. Turk Patoloji Derg. 2020;36:173–7.PubMedPubMedCentral Sachdev R, Mohapatra I, Goel S, Ahlawat K, Sharma N. Core biopsy diagnosis of ALK positive inflammatory myofibroblastic tumor of lung: an interesting case. Turk Patoloji Derg. 2020;36:173–7.PubMedPubMedCentral
21.
22.
go back to reference Antonescu CR, Suurmeijer AJ, Zhang L, et al. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am J Surg Pathol. 2015;39:957–67.CrossRefPubMedPubMedCentral Antonescu CR, Suurmeijer AJ, Zhang L, et al. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am J Surg Pathol. 2015;39:957–67.CrossRefPubMedPubMedCentral
23.
go back to reference Lovly CM, Gupta A, Lipson D, et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov. 2014;4:889–95.CrossRefPubMedPubMedCentral Lovly CM, Gupta A, Lipson D, et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov. 2014;4:889–95.CrossRefPubMedPubMedCentral
24.
go back to reference Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol. 2007;31:509–20.CrossRefPubMed Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol. 2007;31:509–20.CrossRefPubMed
25.
go back to reference Mahajan P, Casanova M, Ferrari A, Fordham A, Trahair T, Venkatramani R. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges. Curr Probl Cancer. 2021;45:100768.CrossRefPubMed Mahajan P, Casanova M, Ferrari A, Fordham A, Trahair T, Venkatramani R. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges. Curr Probl Cancer. 2021;45:100768.CrossRefPubMed
26.
27.
go back to reference Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for T-Cell Lymphomas V.1.2024. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed March 1, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for T-Cell Lymphomas V.1.2024. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed March 1, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org.
30.
go back to reference Mossé YP, Voss SD, Lim MS, et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children’s Oncology Group study. J Clin Oncol. 2017;35:3215–21.CrossRefPubMedPubMedCentral Mossé YP, Voss SD, Lim MS, et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children’s Oncology Group study. J Clin Oncol. 2017;35:3215–21.CrossRefPubMedPubMedCentral
31.
go back to reference Fukano R, Mori T, Sekimizu M, et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial. Cancer Sci. 2020;111:4540–7.CrossRefPubMedPubMedCentral Fukano R, Mori T, Sekimizu M, et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: an open-label phase II trial. Cancer Sci. 2020;111:4540–7.CrossRefPubMedPubMedCentral
32.
go back to reference Knörr F, Schellekens KPJ, Schoot RA, et al. Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma. Haematologica. 2023;108:1442–6.CrossRefPubMed Knörr F, Schellekens KPJ, Schoot RA, et al. Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma. Haematologica. 2023;108:1442–6.CrossRefPubMed
33.
go back to reference Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.3.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed March 1, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.3.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed March 1, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org.
35.
go back to reference Fischer M, Moreno L, Ziegler DS, et al. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. Lancet Oncol. 2021;22:1764–76.CrossRefPubMed Fischer M, Moreno L, Ziegler DS, et al. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. Lancet Oncol. 2021;22:1764–76.CrossRefPubMed
37.
go back to reference Lowe EJ, Reilly AF, Lim MS, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 2021;137:3595–603.CrossRefPubMedPubMedCentral Lowe EJ, Reilly AF, Lim MS, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 2021;137:3595–603.CrossRefPubMedPubMedCentral
39.
go back to reference Stumme H, Lang P, Woessmann W, et al. Combination therapy with crizotinib/brentuximab vedotin in chemorefractory ALK-positive ALCL is feasible and highly effective: a case report [abstract]. Oncol Res Treat. 2015;38:212. Stumme H, Lang P, Woessmann W, et al. Combination therapy with crizotinib/brentuximab vedotin in chemorefractory ALK-positive ALCL is feasible and highly effective: a case report [abstract]. Oncol Res Treat. 2015;38:212.
41.
go back to reference Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18:1590–9.CrossRefPubMedPubMedCentral Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18:1590–9.CrossRefPubMedPubMedCentral
42.
go back to reference Solomon BJ, Bauer TM, Ignatius Ou SH, et al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study. J Clin Oncol. 2022;40:3593–602.CrossRefPubMedPubMedCentral Solomon BJ, Bauer TM, Ignatius Ou SH, et al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study. J Clin Oncol. 2022;40:3593–602.CrossRefPubMedPubMedCentral
43.
go back to reference Solomon BJ, Bauer TM, Mok TSK, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023;11:354–66.CrossRefPubMed Solomon BJ, Bauer TM, Mok TSK, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023;11:354–66.CrossRefPubMed
44.
go back to reference Pearson ADJ, Barry E, Mossé YP, et al. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. Eur J Cancer. 2021;157:198–213.CrossRefPubMed Pearson ADJ, Barry E, Mossé YP, et al. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. Eur J Cancer. 2021;157:198–213.CrossRefPubMed
45.
go back to reference Gambacorti-Passerini C, Mussolin L, Brugieres L. Abrupt relapse of ALK-positive lymphoma after discontinuation of crizotinib. N Engl J Med. 2016;374:95–6.CrossRefPubMed Gambacorti-Passerini C, Mussolin L, Brugieres L. Abrupt relapse of ALK-positive lymphoma after discontinuation of crizotinib. N Engl J Med. 2016;374:95–6.CrossRefPubMed
46.
go back to reference Wang Z, Geng Y, Yuan LY, et al. Durable clinical response to ALK tyrosine kinase inhibitors in epithelioid inflammatory myofibroblastic sarcoma harboring PRRC2B-ALK rearrangement: a case report. Front Oncol. 2022;12:761558.CrossRefPubMedPubMedCentral Wang Z, Geng Y, Yuan LY, et al. Durable clinical response to ALK tyrosine kinase inhibitors in epithelioid inflammatory myofibroblastic sarcoma harboring PRRC2B-ALK rearrangement: a case report. Front Oncol. 2022;12:761558.CrossRefPubMedPubMedCentral
47.
go back to reference Shanmuganathan N, Hughes TP. Molecular monitoring in CML: how deep? How often? How should it influence therapy? Blood. 2018;132:2125–33.CrossRefPubMed Shanmuganathan N, Hughes TP. Molecular monitoring in CML: how deep? How often? How should it influence therapy? Blood. 2018;132:2125–33.CrossRefPubMed
48.
go back to reference Nakai R, Fukuhara S, Maeshima AM, et al. Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin. Clin Case Rep. 2019;7:2500–4.CrossRefPubMedPubMedCentral Nakai R, Fukuhara S, Maeshima AM, et al. Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin. Clin Case Rep. 2019;7:2500–4.CrossRefPubMedPubMedCentral
49.
go back to reference Rigaud C, Knörr F, Brugières L, Woessmann W. Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents. Best Pract Res Clin Haematol. 2023;36: 101444.CrossRefPubMed Rigaud C, Knörr F, Brugières L, Woessmann W. Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents. Best Pract Res Clin Haematol. 2023;36: 101444.CrossRefPubMed
Metadata
Title
Podcast on Emerging Treatment Options for Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumors
Authors
Eric Lowe
Yael P. Mossé
Publication date
27-04-2024
Publisher
Springer Healthcare
Published in
Oncology and Therapy / Issue 2/2024
Print ISSN: 2366-1070
Electronic ISSN: 2366-1089
DOI
https://doi.org/10.1007/s40487-024-00275-6

Other articles of this Issue 2/2024

Oncology and Therapy 2/2024 Go to the issue